Weymann D, Pollard S, Chan B, et al. - This study attempted to calculate within-cohort effects of genomics-informed treatment versus standard care on clinical and cost outcomes. Between 2012 and 2017, researchers focused on adults with advanced cancers enrolled in the single-arm BC Cancer Personalized OncoGenomics program. A total of 346 patients were included in this study cohort, of whom 140 (40%) received genomics-informed treatment after sequencing and 206 (60%) received standard care treatment. Compared with standard care treatment, genomics-informed treatment had a statistically significant effect on TTD, but at increased treatment costs. As per the findings, within-cohort evidence generated through this single-arm study informs the early-stage comparative effectiveness of precision oncology.